Number III: Mucous membrane pemphigoid

Oral Diseases

Volumn 11, Issue 4, 2005, Pages 197-218

  Bagan, J ^a   Muzio, L L ^b   Scully, Crispian ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune; Corticosteroids; Immunosuppressants; Oral; Pemphigoid; Skin

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; BUDESONIDE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DAPSONE; FLUOCINONIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; SULFONAMIDE; TACROLIMUS; TETRACYCLINE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE;

ANTIGENICITY; AUTOIMMUNITY; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENZYME RELEASE; EYE INJURY; GENETIC HETEROGENEITY; HUMAN; LEUKOCYTE; MOUTH LESION; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; AUTOIMMUNE DISEASE; BLISTER; CLASSIFICATION; EPITHELIUM CELL; GINGIVA DISEASE; HEMIDESMOSOME; IMMUNOLOGY; MUCOUS MEMBRANE PEMPHIGOID;

ADRENAL CORTEX HORMONES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLISTER; EPITHELIAL CELLS; GINGIVAL DISEASES; HEMIDESMOSOMES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE;

EID: 23344439422     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2005.01140.x     Document Type: Review

References (276)

1. Ahmed AR, Moy R (1981). Azathioprine. Int J Dermatol 20: 461-467.
2. Ahmed AR, Hombal SM (1984). Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol 11: 1115-1126.
3. Ahmed AR, Hombal SM (1986). Cicatricial pemphigoid. Int J Dermatol 25: 90-96.
4. Ahmed AR, Foster S, Zaltas M et al (1991a). Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci USA 88: 11579-11582.
5. Ahmed AR, Kurgis BS, Rogers RS (1991b). Cicatricial pemphigoid. J Am Acad Dermatol 24: 987-1001.
6. Ahmed AR, Colon JE (2001). Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 137: 1181-1189.
7. Aho S, Uitto J (1999). 180-kD bullous pemphigoid antigen/type XVII collagen: tissue-specific expression and molecular interactions with keratin 18. J Cell Biochem 72: 356-367.
8. Alkan A, Gunhan O, Otan F (2003). A clinical study of oral mucous membrane pemphigoid. J Int Med Res 31: 340-344.
9. Allbritton JI, Nousari HC, Anhalt GJ (1997). Anti-epiligrin (laminin 5) cicatricial pemphigoid. Br J Dermatol 137: 992-996.
10. Anhalt GJ (1990). Pemphigoid. Bullous and cicatricial. Dermatol Clin 8: 701-716.
11. Aractingi S, Bachmeyer C, Prost C, Caux F, Flageul B, Fermand JP (1999). Subepidermal autoimmune bullous skin diseases associated with B-cell lymphoproliferative disorders. Medicine (Baltimore) 78: 228-235.
12. Assmann T, Burchardt T, Becker J, Ruzicka T, Megahed M (2004). Topical immunomodulators: a therapeutic option for oral cicatricial pemphigoid. Hautarzt 55: 390-392.
13. Aufdemorte TB, De Villez RL, Parel SM (1985). Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol 59: 256-260.
14. Azana JM, de Misa RF, Boixeda JP, Ledo A (1993). Topical cyclosporine for cicatricial pemphigoid. J Am Acad Dermatol 28: 134-135.
15. Balding SD, Prost C, Diaz LA et al (1996). Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 106: 141-146.
16. Barnadas MA, Gelpi C, Curell R, de Moragas JM, Alomar A (1999). Repeat direct immunofluorescence (DIF) test, using, 1 M NaCl treated skin, in the subepidermal autoimmune bullous diseases that contain IgG at the dermal epidermal junction. J Cutan Pathol 26: 37-41.
17. Barnadas MA, Gonzalez MJ, Planaguma M et al (2001). Clinical, histopathologic, and therapeutic aspects of subepidermal autoimmune bullous diseases with IgG on the floor of salt-split skin. Int J Dermatol 40: 268-272.
18. Bauco van der Wal V, Jonkman MF (1997). Topical tetracycline in cicatricial pemphigoid. J Am Acad Dermatol 36: 492-493.
19. Bedane C, Prost C, Bernard P, Catanzano G, Bonnetblanc JM, Dubertret L (1991). Cicatricial pemphigoid antigen differs from bullous pemphigoid antigen by its exclusive extracellular localization: a study by indirect immunoelectronmicroscopy. J Invest Dermatol 97: 3-9.
20. Bedane C, McMillan JR, Balding SD et al (1997). Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 108: 901-907.
21. Bernard P, Prost C, Durepaire N, Basset-Seguin N, Didierjean L, Saurat JH (1992). The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J Invest Dermatol 99: 174-179.
22. Bernard P, Vaillant L, Labeille B et al (1995). Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 131: 48-52.
23. Beutner EH, Jordon RE, Chorzelski TP (1968). The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 51: 63-80.
24. Bhan AK, Fujikawa LS, Foster CS (1982). T-cell subsets and Langerhans cells in normal and diseased conjunctiva. Am J Ophthalmol 94: 205-212.
25. Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, Ahmed AR (2000). The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J Immunol 165: 2824-2829.
26. Bhol KC, Goss L, Kumari S, Colon JE, Ahmed AR (2001). Autoantibodies to human alpha6 integrin in patients with oral pemphigoid. J Dent Res 80: 1711-1715.
27. Boedeker CC, Termeer CC, Staats R, Ridder GJ (2003). Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. Ann Otol Rhinol Laryngol 112: 271-275.
28. Bohn J, Jonsson S, Holst R (1999). Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cyclophosphamide. Br J Dermatol 141: 536-540.
29. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD (1992). Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 98: 135-140.
30. Borrego L, Maynard B, Peterson EA et al (1996). Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 148: 897-909.
31. Brody HJ, Pirozzi DJ (1977). Benign mucous membrane pemphigoid. Response to therapy with cyclophosphamide. Arch Dermatol 113: 1598-1599.
32. Budinger L, Borradori L, Yee C et al (1998). Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102: 2082-2089.
33. Burton JL, Harman RR, Peachey RD, Warin RP (1978). Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 2: 1190-1191.
34. Caproni M, Calzolari A, Giomi B, Santucci M, Ficarra G, Fabbri P (2002). IL-4, IL-5, TGF-beta1 and IFN-gamma mRNAs detected by a new in situ amplification system in cicatricial pemphigoid. Exp Dermatol 11: 421-427.
35. Caproni M, Calzolari A, Salvatore E et al (2003). Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid. J Oral Pathol Med 32: 34-40.
36. Carbone M, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, Gandolfo S (1998). Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial. Minerva Stomatol 47: 479-487.
37. Carrozzo M, Broccoletti R, Carbone M, Garzino-Demo P, Gandolfo S (1996). Pemphigoid of the mucous membranes. The clinical, histopathological and immunological aspects and current therapeutic concepts. Minerva Stomatol 45: 455-463.
38. Carrozzo M, Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S (1997). Therapeutic management of mucous membrane pemphigoid. Report of 11 cases. Minerva Stomatol 46: 553-559.
39. Carrozzo M, Fasano ME, Broccoletti R et al (2001). HLA-DQB1 alleles in Italian patients with mucous membrane pemphigoid predominantly affecting the oral cavity. Br J Dermatol 145: 805-808.
40. Casiglia J, Woo SB, Ahmed AR (2001). Oral involvement in autoimmune blistering diseases. Clin Dermatol 19: 737-741.
41. Challacombe SJ, Setterfield J, Shirlaw P, Harman K, Scully C, Black MM (2001). Immunodiagnosis of pemphigus and mucous membrane pemphigoid. Acta Odontol Scand 59: 226-234.
42. Chan LS, Fine JD, Briggaman RA et al (1993a). Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol 101: 262-267.
43. Chan LS, Yancey KB, Hammerberg C et al (1993b). Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Arch Dermatol 129: 448-455.
44. Chan LS, Cooper KD (1994). A novel immune-mediated subepidermal bullous dermatosis characterized by IgG autoantibodies to a lower lamina lucida component. Arch Dermatol 130: 343-347.
45. Chan LS, Hammerberg C, Cooper KD (1997a). Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid. J Invest Dermatol 108: 129-132.
46. Chan LS, Majmudar AA, Tran HH et al (1997b). Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 108: 848-853.
47. Chan LS (2001). Mucous membrane pemphigoid. Clin Dermatol 19: 703-711.
48. Chan LS, Ahmed AR, Anhalt GJ et al (2002). The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 138: 370-379.
49. Chan RY, Bhol K, Tesavibul N et al (1999). The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 40: 2283-2290.
50. Chen KR, Shimizu S, Miyakawa S, Ishiko A, Shimizu H, Hashimoto T (1996). Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis: identification of a novel 200-kDa lower lamina lucida target antigen. Br J Dermatol 134: 340-346.
51. Cheng YS, Rees TD, Wright JM, Plemons JM (2001). Childhood oral pemphigoid: a case report and review of the literature. J Oral Pathol Med 30: 372-377.
52. Christophoridis S, Budinger L, Borradori L, Hunziker T, Merk HF, Hertl M (2000). IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 143: 349-355.
53. Chuh AA (2004). The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol 150: 622-623.
54. Ciarrocca KN, Greenberg MS (1999). A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Sur g Oral Med Oral Pathol Oral Radiol Endod 88: 159-163.
55. Cole WC, Leicht S, Byrd RP Jr, Roy TM (2000). Cicatricial pemphigoid with an upper airway lesion. Tenn Med 93: 99-101.
56. Czech W, Schaller J, Schopf E, Kapp A (1993). Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 29: 210-215.
57. Dabelsteen E (1998). Molecular biological aspects of acquired bullous diseases. Crit Rev Oral Biol Med 9: 162-178.
58. Daniels TE, Quadra-White C (1981). Direct immunofluorescence in oral mucosal disease: a diagnostic analysis of 130 cases. Oral Surg Oral Med Oral Pathol 51: 38-47.
59. D'Auria L, Cordiali Fei P, Ameglio F (1999). Cytokines and bullous pemphigoid. Eur Cytokine Netw 10: 123-134.
60. Dave VK, Vickers CF (1974). Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 90: 183-186.
61. Dayan S, Simmons RK, Ahmed AR (1999). Contemporary issues in the diagnosis of oral pemphigoid: a selective review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 424-430.
62. Delgado JC, Turbay D, Yunis EJ et al (1996). A common major histocompatibility complex class II allele HLA-DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 93: 8569-8571.
63. Doan S, Lerouic JF, Robin H, Prost C, Savoldelli M, Hoang-Xuan T (2001). Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 108: 1565-1568.
64. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992). Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 90: 1628-1633.
65. Domloge-Hultsch N, Anhalt GJ, Gammon WR et al (1994). Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 130: 1521-1529.
66. Dragan L, Eng AM, Lam S, Persson T (1999). Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. Cutis 63: 181-183.
67. Duong DJ, Moxley RT III, Kellman RM, Pincus SH, Gaspari AA (2002). Thalidomide therapy for cicatricial pemphigoid. J Am Acad Dermatol 47: S193-S195.
68. Egan CA, Hanif N, Taylor TB, Meyer LJ, Petersen MJ, Zone JJ (1999a). Characterization of the antibody response in oesophageal cicatricial pemphigoid. Br J Dermatol 140: 859-864.
69. Egan CA, Taylor TB, Meyer LJ, Petersen MJ, Zone JJ (1999b). The immunoglobulin A antibody response in clinical subsets of mucous membrane pemphigoid. Dermatology 198: 330-335.
70. Egan CA, Yancey KB (2000). The clinical and immunopathological manifestations of anti-epiligrin cicatricial pemphigoid, a recently defined subepithelial autoimmune blistering disease. Eur J Dermatol 10: 585-589.
71. Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB (2001). Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 357: 1850-1851.
72. Egan CA, Yee C, Zillikens D, Yancey KB (2002). Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease. J Am Acad Dermatol 46: 786-789.
73. Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB (2003). Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 82: 177-186.
74. Eisen D, Ellis CN, Voorhees JJ (1990). Topical cyclosporine for oral bullous disorders. J Am Acad Dermatol 23: 936-937.
75. Engineer L, Bhol K, Kumari S, Razzaque Ahmed A (2001). Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation. Cytokine 13: 32-38.
76. Epstein JB, Gorsky M, Epstein MS, Nantel S (2001). Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91: 56-61.
77. Eversole LR (1994). Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 77: 555-571.
78. Eversole LR (1996). Adhesion molecules and oral mucosal diseases. Oral Dis 2: 185-187.
79. Fine JD (1995). Management of acquired bullous skin diseases. N Engl J Med 333: 1475-1484.
80. Fine RM, Weathers DR (1980). Desquamative gingivitis: a form of cicatricial pemphigoid? Br J Dermatol 102: 393-399.
81. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D (1994). Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130: 753-758.
82. Fleming TE, Korman NJ (2000). Cicatricial pemphigoid. J Am Acad Dermatol 43: 571-591 (quiz 591-594).
83. Foster CS (1986). Cicatricial pemphigoid. Trans Am Ophthalmol Soc 84: 527-663.
84. Foster CS, Ahmed AR (1999). Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 106: 2136-2143.
85. Fueston JC, Adams BB, Mutasim DF (2002). Cicatricial pemphigoid-induced phimosis. J Am Acad Dermatol 46: S128-S129.
86. Fujimoto W, Ishida-Yamamoto A, Hsu R et al (1998). Anti-epiligrin cicatricial pemphigoid: a case associated with gastric carcinoma and features resembling epidermolysis bullosa acquisita. Br J Dermatol 139: 682-687.
87. Fujimoto W, Toi Y, Okazaki F, Lazarova Z, Yancey KB, Arata J (1999). Anti-epiligrin cicatricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5. J Am Acad Dermatol 40: 637-639.
88. Gallagher G, Shklar G (1987). Oral involvement in mucous membrane pemphigoid. Clin Dermatol 5: 18-27.
89. Gammon WR, Briggaman RA, Inman AO III, Queen LL, Wheeler CE (1984). Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 82: 139-144.
90. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH (1990). Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 22: 664-670.
91. Gately LE III, Nesbitt LT Jr (1994). Update on immunofluorescent testing in bullous diseases and lupus erythematosus. Dermatol Clin 12: 133-142.
92. Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL (1996). Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol 107: 136-139.
93. Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL (1997b). Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 133: 1102-1107.
94. Gibson GE, Daoud MS, Pittelkow MR (1997). Anti-epiligrin (laminin 5) cicatricial pemphigoid and lung carcinoma: coincidence or association? Br J Dermatol 137: 780-782.
95. Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A et al (2003). Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 688-692.
96. Gunther C, Wozel G, Meurer M, Pfeiffer C (2004). Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol 50: 325-326.
97. Hall VC, Liesegang TJ, Kostick DA, Lookingbill DP (2003). Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 139: 1083-1084.
98. Hanson RD, Olsen KD, Rogers RS III (1988). Upper aerodigestive tract manifestations of cicatricial pemphigoid. Ann Otol Rhinol Laryngol 97: 493-499.
99. Hardy KM, Perry HO, Pingree GC, Kirby TJ Jr (1971). Benign mucous membrane pemphigoid. Arch Dermatol 104: 467-475.
100. Hashimoto T, Murakami H, Senboshi Y et al (1996). Antiepiligrin cicatricial pemphigoid: the first case report from Japan. J Am Acad Dermatol 34: 940-942.
101. Hashimoto Y, Suga Y, Yoshiike T, Hashimoto T, Takamori K (2000). A case of antiepiligrin cicatricial pemphigoid successfully treated by plasmapheresis. Dermatology 201: 58-60.
102. Helander SD, Rogers RS III (1994). The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol 30: 65-75.
103. Hisamatsu Y, Nishiyama T, Amano S, Matsui C, Ghohestani R, Hashimoto T (2003). Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci 33: 113-119.
104. Hoang-Xuan T, Robin H, Demers PE et al (1999). Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid. Ophthalmology 106: 355-361.
105. Holmstrup P, Schiotz AW, Westergaard J (1990). Effect of dental plaque control on gingival lichen planus. Oral Surg Oral Med Oral Pathol 69: 585-590.
106. Horiguchi Y, Ueda M, Shimizu H et al (1996). An acquired bullous dermatosis due to an autoimmune reaction against uncein. Br J Dermatol 134: 934-938.
107. Hsu R, Lazarova Z, Yee C, Yancey KB (1997). Noncomplement fixing, IgG4 autoantibodies predominate in patients with anti-epiligrin cicatricial pemphigoid. J Invest Dermatol 109: 557-561.
108. Hsu RC, Lazarova Z, Lee HG, Tung YC, Yu HS (2000). Antiepiligrin cicatricial pemphigoid. J Am Acad Dermatol 42: 841-844.
109. Huilgol SC, Black MM (1995). Management of the immunobullous disorders. I. Pemphigoid. Clin Exp Dermatol 20: 189-201.
110. Humbert P, Treffel P, Chapuis JF, Buchet S, Derancourt C, Agache P (1991). The tetracyclines in dermatology. J Am Acad Dermatol 25: 691-697.
111. Ikegaya H, Kato A, Matsushima H, Takai K, Hosaka Y, Kitamura T (1999). A case of cicatricial pemphigoid producing severe dysuria due to labial adhesion. BJU Int 83: 735-736.
112. Jolles S (2001). A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 26: 127-131.
113. Jones J, Downer CS, Speight PM (1995). Changes in the expression of integrins and basement membrane proteins in benign mucous membrane pemphigoid. Oral Dis 1: 159-165.
114. Karpouzis A, Vamvassakis E, Stavrianeas N, Koumantaki-Mathioudaki E, Karpouzi M, Vareltzides A (2002). Ultrastructural immunocytochemistry of autoimmune bullous diseases. Australas J Dermatol 43: 113-119.
115. Kawahara Y, Amagai M, Ohata Y et al (1998). A case of cicatricial pemphigoid with simultaneous IgG autoantibodies against the 180 kd bullous pemphigoid antigen and laminin 5. J Am Acad Dermatol 38: 624-627.
116. Kawahara Y, Zillikens D, Yancey KB et al (2000). Subepidermal blistering disease with autoantibodies against a novel dermal 200-kDa antigen. J Dermatol Sci 23: 93-102.
117. Kazama T, Yamamoto Y, Hashimoto T, Komai A, Ito M (1998). Application of confocal laser scanning microscopy to differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Br J Dermatol 138: 593-601.
118. Kelly SE, Wojnarowska F (1988). The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 118: 31-40.
119. Kim Y, Greenberg MS (2001). Management of patients with severe oral mucosal disease. Alpha Omegan 94: 18-23.
120. Kirtschig G, Marinkovich MP, Burgeson RE, Yancey KB (1995). Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 105: 543-548.
121. Kirtschig G, Mittag H, Wolf M, Gorski A, Happle R (1999). Three different autoimmune bullous diseases in one family: is there a common genetic base? Br J Dermatol 140: 322-327.
122. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N (2003). Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev CD004056.
123. Korman NJ, Watson RD (1996). Immune-mediated subepithelial blistering diseases of the mucous membranes. Improving the detection of circulating autoantibodies by the use of concentrated serum samples. Arch Dermatol 132: 1194-1198.
124. Kreyden OP, Borradori L, Trueb RM, Burg G, Nestle FO (2001). Successful therapy with tetracycline and nicotinamide in cicatricial pemphigoid. Hautarzt 52: 247-250.
125. Kromminga A, Sitaru C, Meyer J et al (2002). Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain. J Dermatol Sci 28: 68-75.
126. Kuenzli S, Grimaitre M, Krischer J, Saurat JH, Calza AM, Borradori L (2004). Childhood bullous pemphigoid: report of a case with life-threatening course during homeopathy treatment. Pediatr Dermatol 21: 160-163.
127. Kuffer R (1996). Bulous disease. In: Porter SR, Scully C, eds. Innovations and developments in non-invasive orofacial healthcare. Science Reviews: Northwood, pp. 109-126.
128. Kumari S, Bhol KC, Rehman F, Foster CS, Ahmed AR (2001a). Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine 14: 218-224.
129. Kumari S, Bhol KC, Simmons RK et al (2001b). Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest Ophthalmol Vis Sci 42: 379-385.
130. Kurzhals G, Stolz W, Maciejewski W, Karpati S, Meurer M, Breit R (1995). Localized cicatricial pemphigoid of the Brunsting-Perry type with transition into disseminated cicatricial pemphigoid. Report of a case proved by preembedding immunogold electron microscopy. Arch Dermatol 131: 580-585.
131. Lamey PJ, Jones CM (1988). Desquamative gingivitis treated with occlusive steroid therapy: a pilot study. Gerodontics 4: 188-190.
132. Lamey PJ, Rees TD, Binnie WH, Rankin KV (1992). Mucous membrane pemphigoid. Treatment experience at two institutions. Oral Surg Oral Med Oral Pathol 74: 50-53.
133. Laskaris G, Nicolis G (1980). Immunopathology of oral mucosa in bullous pemphigoid. Oral Surg Oral Med Oral Pathol 50: 340-345.
134. Laskaris G, Angelopoulos A (1981). Cicatricial pemphigoid: direct and indirect immunofluorescent studies. Oral Surg Oral Med Oral Pathol 51: 48-54.
135. Laskaris G, Sklavounou A, Stratigos J (1982). Bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris. A comparative clinical survey of 278 cases. Oral Surg Oral Med Oral Pathol 54: 656-662.
136. Laskaris G, Satriano RA (1993). Drug-induced blistering oral lesions. Clin Dermatol 11: 545-550.
137. Lazarova Z, Yancey KB (1996). Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin. Specificity, sensitivity, and practical considerations. J Am Acad Dermatol 35: 398-403.
138. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB (1996). Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98: 1509-1518.
139. Lazarova Z, Hsu R, Briggaman RA, Yancey KB (2000a). Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin Immunol 95: 26-32.
140. Lazarova Z, Hsu R, Yee C, Yancey KB (2000b). Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model. J Invest Dermatol 114: 178-184.
141. Lazarova Z, Yee C, Lazar J, Yancey KB (2001). IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 101: 100-105.
142. Le Rouic JF, Robin H, Doan S, Prisant O, Belayachi N, Hoang-Xuan T (1999). Treatment of ocular cicatricial pemphigoid with sulfasalazine. J Fr Ophtalmol 22: 423-425.
143. Lee JB, Liu Y, Hashimoto T (2003). Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180. J Dermatol Sci 32: 59-64.
144. Lenz P, Hsu R, Yee C et al (1998). Cicatricial pemphigoid with autoantibodies to laminin 5 (epiligrin) in a patient with metastatic endometrial carcinoma. Hautarzt 49: 31-35.
145. Leonard JN, Haffenden GP, Ring NP et al (1982). Linear IgA disease in adults. Br J Dermatol 107: 301-316.
146. Leonard JN, Wright P, Williams DM et al (1984). The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 110: 307-314.
147. Letko E, Bhol K, Foster SC, Ahmed RA (2000). Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr Eye Res 21: 646-654.
148. Letko E, Ahmed AR, Foster CS (2001). Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 239: 441-444.
149. Lever WF (1953). Pemphigus. Medicine (Baltimore) 32: 1-123.
150. Leverkus M, Schmidt E, Lazarova Z, Brocker EB, Yancey KB, Zillikens D (1999). Antiepiligrin cicatricial pemphigoid: an under diagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? Arch Dermatol 135: 1091-1098.
151. Leverkus M, Bhol K, Hirako Y et al (2001). Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol 145: 998-1004.
152. Leverkus M, Georgi M, Nie Z, Hashimoto T, Brocker EB, Zillikens D (2002). Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol 46: 116-122.
153. Lilly JP, Spivey JD, Fotos PG (1995). Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy. J Periodontol 66: 737-741.
154. Lin MS, Gharia MA, Swartz SJ, Diaz LA, Giudice GJ (1999). Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol 162: 4991-4991.
155. Lin MS, Fu CL, Giudice GJ et al (2000). Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 115: 955-961.
156. Lish KM, Washenik K, Yancey KB, Yee C, Rico MJ (1997). Anti-epiligrin cicatricial pemphigoid in a patient with HIV. J Am Acad Dermatol 36: 486-488.
157. Liu HN, Su WP, Rogers RS III (1986). Clinical variants of pemphigoid. Int J Dermatol 25: 17-27.
158. Liu V, Mackool BT (2003). Mycophenolate in dermatology. J Dermatolog Treat 14: 203-211.
159. Liu Z, Shapiro SD, Zhou X et al (2000a). A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105: 113-123.
160. Liu Z, Zhou X, Shapiro SD et al (2000b). The serpin alpha 1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102: 647-655.
161. Lozada F, Silverman S Jr (1980). Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol 116: 898-901.
162. Lozada F (1981). Prednisone and azathioprine in the treatment of patient with vesiculoerosive oral diseases. Oral Surg Oral Med Oral Pathol 52: 257-263.
163. Lozada-Nur F, Huang MZ, Zhou GA (1991). Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 71: 283-287.
164. Lozada-Nur F, Miranda C, Maliksi R (1994). Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 77: 598-604.
165. Mallon E, Wojnarowska F (1994). Cicatricial pemphigoid presenting with unusual palmar involvement, successfully treated with a combination of nicotinamide and tetracycline. Clin Exp Dermatol 19: 526-530.
166. Manton SL, Scully C (1988). Mucous membrane pemphigoid: an elusive diagnosis? Oral Surg Oral Med Oral Pathol 66: 37-40.
167. Mascaro JM Jr, Zillikens D, Giudice GJ et al (2000). A subepidermal bullous eruption associated with IgG autoantibodies to a 200 kd dermal antigen: the first case report from the United States. J Am Acad Dermatol 42: 309-315.
168. Matsushima S, Horiguchi Y, Honda T et al (2004). A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol 31: 10-15.
169. Matthews RW, Pinkney RC, Scully C (1989). The management of intransigent desquamative gingivitis with Dapsone. Ann Dent 48: 41-43.
170. McCluskey P, Chang JH, Singh R, Wakefield D (2004). Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 111: 796-801.
171. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L (1989). Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 121: 759-762.
172. McGowan KA, Marinkovich MP (2000). Laminins and human disease. Microsc Res Tech 51: 262-279.
173. Meyer JR, Migliorati CA, Daniels TE, Greenspan JS (1985). Localization of basement membrane components in mucous membrane pemphigoid. J Invest Dermatol 84: 105-107.
174. Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS (2002). The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 109: 111-118.
175. Miziara ID, Sperandio F, Bohadana SC, Braga N, Romano FR, Miniti A (2002). Cicatricial pemphigoid: report of five cases. Ear Nose Throat J 81: 442-448.
176. Mobini N, Nagarwalla N, Ahmed AR (1998). Oral pemphigoid. Subset of cicatricial pemphigoid? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 37-43.
177. Mondino BJ, Brown SI (1981). Ocular cicatricial pemphigoid. Ophthalmology 88: 95-100.
178. Moy W, Kumar V, Friedman RP, Schaeffer ML, Beutner E, Helm F (1986). Cicatricial pemphigoid. A case of onset at age 5. J Periodontol 57: 39-43.
179. Musa NJ, Kumar V, Humphreys L, Aguirre A, Neiders ME (2002). Oral pemphigoid masquerading as necrotizing ulcerative gingivitis in a child. J Periodontol 73: 657-663.
180. Musette P, Pascal F, Hoang-Xuan T et al (2001). Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide. Arch Dermatol 137: 101-102.
181. Mutasim DF, Pelc NJ, Anhalt GJ (1993). Cicatricial pemphigoid. Dermatol Clin 11: 499-510.
182. Mutasim DF (1997). The accuracy of indirect immunofluorescence on sodium chloride-split skin in differentiating subepidermal bullous diseases. Arch Dermatol 133: 1158-1160.
183. Mutasim DF, Adams BB (2000). Cicatricial pemphigoid diagnosed by the use
184. Nayar M, Wojnarowska F, Venning V, Taylor CJ (1991). Association of autoimmunity and cicatricial pemphigoid: is there an immunogenetic basis? J Am Acad Dermatol 25: 1011-1015.
185. Nayar M, Wojnarowska F (1993). Cicatricial pemphigoid: a re-evaluation of therapy. J Dermatol Treatment 4: 89-93.
186. Nie Z, Hashimoto T (1999). IgA antibodies of cicatricial pemphigoid sera specifically react with C-terminus of BP180. J Invest Dermatol 112: 254-255.
187. Nousari HC, Anhalt GJ (1999). Pemphigus and bullous pemphigoid. Lancet 354: 667-672.
188. Nousari HC, Anhalt GJ (1995). Bullous skin diseases. Curr Opin Immunol 7: 844-852.
189. Nousari HC, Rencic A, Hsu R, Yancey KB, Anhalt GJ (1999). Anti-epiligrin cicatricial pemphigoid with antibodies against the gamma2 subunit of laminin 5. Arch Dermatol 135: 173-176.
190. Oostingh GJ, Sitaru C, Kromminga A, Dormann D, Zillikens D (2002). Autoreactive T cell responses in pemphigus and pemphigoid. Autoimmun Rev 1: 267-272.
191. Ozog DM, Gogstetter DS, Scott G, Gaspari AA (2000). Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 136: 1133-1138.
192. Parisi E, Raghavendra S, Werth VP, Sollecito TP (2003). Modification to the approach of the diagnosis of mucous membrane pemphigoid: A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 182-186.
193. Park JH, Chun HJ, Jeen YT et al (2002). Esophageal cicatricial pemphigoid. Gastrointest Endosc 55: 909.
194. Poon E, McGrath JA (1999). Non-specific scalp crusting as a presenting feature of Brunsting-Perry cicatricial pemphigoid. J Eur Acad Dermatol Venereol 12: 177-178.
195. Porter SR, Scully C, Midda M, Eveson JW (1990). Adult linear immunoglobulin A disease manifesting as desquamative gingivitis. Oral Surg Oral Med Oral Pathol 70: 450-453.
196. Poskitt L, Wojnarowska F (1995a). Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol 132: 784-789.
197. Poskitt L, Wojnarowska F (1995b). Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol 20: 258-259.
198. Prost C, Labeille B, Chaussade V, Guillaume JC, Martin N, Dubertret L (1987). Immunoelectron microscopy in subepidermal autoimmune bullous diseases: a prospective study of IgG and C3 bound in vivo in 32 patients. J Invest Dermatol 89: 567-573.
199. Provost TT, Maize JC, Ahmed AR, Strauss JS, Dobson RL (1979). Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. Arch Dermatol 115: 156-160.
200. Razzaque MS, Ahmed AR (2002). Collagens, collagen-binding heat shock protein 47 and transforming growth factor-beta 1 are induced in cicatricial pemphigoid: possible role(s) in dermal fibrosis. Cytokine 17: 311-316.
201. Razzaque MS, Foster CS, Ahmed AR (2002). Role of enhanced expression of m-CSF in conjunctiva affected by cicatricial pemphigoid. Invest Ophthalmol Vis Sci 43: 2977-2983.
202. Rice BA, Foster CS (1990). Immunopathology of cicatricial pemphigoid affecting the conjunctiva. Ophthalmology 97: 1476-1483.
203. Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RP III (1999). Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol 140: 1079-1086.
204. Robin H, Hoang-Xuan T, Prisant O, Toublanc M, Prost C (1999). Immunoelectron microscopic study of the conjunctiva in cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 237: 39-44.
205. Rogers III RS, Seehafer JR, Perry HO (1982). Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 6: 215-223.
206. Rogers III RS (1986). Dapsone and sulfapyridine therapy of pemphigoid diseases. Australas J Dermatol 27: 58-63.
207. Rogers III RS, Mehregan DA (1988). Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1: 201-205.
208. Roh JY, Yee C, Lazarova Z, Hall RP, Yancey KB (2000). The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. Br J Dermatol 143: 104-111.
209. Ronbeck BA, Lind PO, Thrane PS (1990). Desquamative gingivitis: preliminary observations with tetracycline treatment. Oral Surg Oral Med Oral Pathol 69: 694-697.
210. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N (2002). Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 46: 113-115.
211. Sacks EH, Jakobiec FA, Wieczorek R, Donnenfeld E, Perry H, Knowles Jr DM (1989). Immunophenotypic analysis of the inflammatory infiltrate in ocular cicatricial pemphigoid. Further evidence for a T cell-mediated disease. Ophthalmology 96: 236-243.
212. Sakamoto K, Mori K, Hashimoto T, Yancey KB, Nakashima T (2002). Antiepiligrin cicatricial pemphigoid of the larynx successfully treated with a combination of tetracycline and niacinamide. Arch Otolaryngol Head Neck Surg 128: 1420-1423.
213. Sallout H, Anhalt GJ, Al-Kawas FH (2000). Mucous membrane pemphigoid presenting with isolated esophageal involvement: a case report. Gastrointest Endosc 52: 429-433.
214. Sami N, Ahmed AR (2001). Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature. Dermatology 202: 293-301.
215. Sami N, Bhol KC, Beutner EH et al (2001). Simultaneous presence of mucous membrane pemphigoid and pemphigus vulgaris: molecular characterization of both autoantibodies. Clin Immunol 100: 219-227.
216. Sami N, Bhol KC, Ahmed AR (2002a). Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 129: 533-540.
217. Sami N, Bhol KC, Razzaque Ahmed A (2002b). Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 102: 59-67.
218. Schmidt E, Reimer S, Kruse N et al (2000). Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 115: 842-848.
219. Schmidt E, Zillikens D (2000). Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 16: 113-157 (discussion 158).
220. Schmidt E, Reimer S, Kruse N, Brocker EB, Zillikens D (2001a). The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 124: 157-162.
221. Schmidt E, Skrobek C, Kromminga A et al (2001b). Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 145: 778-783.
222. Schmidt E, Kromminga A, Mimietz S et al (2002). A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. J Autoimmun 18: 299-309.
223. Schmidt E, Wehr B, Tabengwa EM, Reimer S, Brocker EB, Zillikens D (2004). Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin Exp Immunol 135: 497-504.
224. Schumann H, Amann U, Tasanen K et al (1999). A child with localized vulval pemphigoid and IgG autoantibodies targeting the C-terminus of collagen XVII/BP180. Br J Dermatol 140: 1133-1138.
225. Schumann H, Baetge J, Tasanen K et al (2000). The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 156: 685-695.
226. Sciubba JJ (1996). Autoimmune aspects of pemphigus vulgaris and mucosal pemphigoid. Adv Dent Res 10: 52-56.
227. Scott JE, Ahmed AR (1998). The blistering diseases. Med Clin North Am 82: 1239-1283.
228. Scully C, Porter SR (1997). The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg 16: 308-313.
229. Scully C, Cawson RA (2004). Medical problems in dentistry, 5th edn. Churchill Livingstone: London.
230. Scully C, Carrozzo M, Gandolfo S, Puiatti P, Monteil R (1999). Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 56-68.
231. Seo SH, Kye YC, Kim SN, Kim SC (2001). Antiepiligrin cicatricial pemphigoid with autoantibodies to the beta subunit of laminin 5 and associated with severe laryngeal involvement necessitating tracheostomy. Dermatology 202: 63-66.
232. Setterfield J, Shirlaw PJ, Kerr-Muir M et al (1998). Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol 138: 602-610.
233. Setterfield J, Shirlaw PJ, Bhogal BS, Tilling K, Challacombe SJ, Black MM (1999a). Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity. Br J Dermatol 140: 645-650.
234. Setterfield J, Shirlaw PJ, Lazarova Z et al (1999b). Paraneoplastic cicatricial pemphigoid. Br J Dermatol 141: 127-131.
235. Setterfield J, Theron J, Vaughan RW et al (2001). Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 145: 406-414.
236. Shannon JF, Mackenzie-Wood A, Wood G, Goldstein D (2003). Cicatricial pemphigoid in non-Hodgkin's lymphoma. Intern Med J 33: 396-397.
237. Shimanovich I, Hirako Y, Sitaru C et al (2003). The autoantigen of anti-p200 pemphigoid is an acidic noncollagenous N-linked glycoprotein of the cutaneous basement membrane. J Invest Dermatol 121: 1402-1408.
238. Shimizu H, Masunaga T, Ishiko A et al (1995). Autoantibodies from patients with cicatricial pemphigoid target different sites in epidermal basement membrane. J Invest Dermatol 104: 370-373.
239. Shklar G, McCarthy CP (1959). Oral manifestations of benign mucous membrane pemphigus (mucous membrane pemphigoid); review of the literature and report of fifteen cases. J Oral Surg (Chic) 12: 950-966.
240. Shklar G, McCarthy PL (1971). Oral lesions of mucous membrane pemphigoid. A study of 85 cases. Arch Otolaryngol 93: 354-364.
241. Shore JW, Foster CS, Westfall CT, Rubin PA (1992). Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid. Ophthalmology 99: 383-395.
242. Siegel MA, Anhalt GJ (1993). Direct immunofluorescence of detached gingival epithelium for diagnosis of cicatricial pemphigoid. Report of five cases. Oral Surg Oral Med Oral Pathol 75: 296-302.
243. Siegel MA, Balciunas BA (1994). Oral presentation and management of vesiculobullous disorders. Semin Dermatol 13: 78-86.
244. Silverman S Jr, Gorsky M, Lozada-Nur F, Liu A (1986). Oral mucous membrane pemphigoid. A study of sixty-five patients. Oral Surg Oral Med Oral Pathol 61: 233-237.
245. Sklavounou A, Laskaris G (1990). Childhood cicatricial pemphigoid with exclusive gingival involvement. Int J Oral Maxillofac Surg 19: 197-199.
246. Smith EP, Taylor TB, Meyer LJ, Zone JJ (1993). Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 101: 619-623.
247. Stahle-Backdahl M, Inoue M, Guidice GJ, Parks WC (1994). 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 93: 2022-2030.
248. Steepler ET, DeRossi SS, Sollecito TP (2003a). Mucous membrane pemphigoid. Update for the general practitioner. N Y State Dent J 69: 28-31.
249. Stoopler ET, Sollecito TP, DeRossi SS (2003b). Desquamative gingivitis: early presenting symptom of mucocutaneous disease. Quintessence Int 34: 582-586.
250. Taniuchi K, Takata M, Matsui C et al (1999). Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol 140: 696-700.
251. Thong YH, Ferrante A (1979). Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol 35: 443-446.
252. Thornhill M, Pemberton M, Buchanan J, Theaker E (2000). An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid. Br J Dermatol 143: 117-126.
253. Truhan AP, Ahmed AR (1989). Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 62: 375-391.
254. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR (1996). Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA 93: 14714-14719.
255. Uchiyama K, Yamamoto Y, Taniuchi K, Matsui C, Fushida Y, Shirao Y (2000). Remission of antiepiligrin (laminin-5) cicatricial pemphigoid after excision of gastric carcinoma. Cornea 19: 564-566.
256. Urbanek VE, Cohen L (1971). Benign mucous membrane pemphigoid. Management of an edentulous patient. Oral Surg Oral Med Oral Pathol 31: 772-776.
257. Vaillant L, Arbeille B, Goga D, de Muret A, Prime A, Lorette G (1990). Cicatricial pemphigoid disclosed by superficial desquamative gingivitis. Clinical and immuno-electron microscopic study of a case. Ann Dermatol Venereol 117: 613-620.
258. Van Joost T, Van't Veen AJ (1993). Drug-induced cicatricial pemphigoid and acquired epidermolysis bullosa. Clin Dermatol 11: 521-527.
259. Venning VA, Frith PA, Bron AJ, Millard PR, Wojnarowska F (1988). Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol 118: 7-15.
260. Venning VA, Dean D, Wojnarowska F (1992). Absence of expression of class II major histocompatibility complex determinants on keratinocytes in bullous pemphigoid. Br J Dermatol 126: 463-467.
261. Verdolini R, Cerio R (2003). Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist. Virchows Arch 443: 184-193.
262. Vincent SD, Lilly GE, Baker KA (1993). Clinical, historic, and therapeutic features of cicatricial pemphigoid. A literature review and open therapeutic trial with corticosteroids. Oral Surg Oral Med Oral Pathol 76: 453-459.
263. Vodegel RM, de Jong MC, Pas HH, Yancey KB, Jonkman MF (2003). Anti-epiligrin cicatricial pemphigoid and epidermolysis bullosa acquisita: differentiation by use of indirect immunofluorescence microscopy. J Am Acad Dermatol 48: 542-547.
264. Weinberg MA, Insler MS, Campen RB (1997). Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84: 517-534.
265. Whiteside OJ, Martinez Devesa P, Ali I, Capper JW (2003). Mucous membrane pemphigoid: nasal and laryngeal manifestations. J Laryngol Otol 111: 885-888.
266. Wojnarowska F, Marsden RA, Bhogal B, Black MM (1988). Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 19: 792-805.
267. Wozel G, Pfeiffer C (2002). Leflunomide - a new drug for pharmacological immunomodulation. Hautarzt 53: 309-315.
268. Wozniak K, Kazama T, Kowalewski C (2003). A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy. Arch Dermatol 139: 1007-1011.
269. Wray D, McCord JF (1987). Labial veneers in the management of desquamative gingivitis. Oral Surg Oral Med Oral Pathol 64: 41-42.
270. Yancey KB, Kirtschig G, Yee C, Lazarova Z (1995). Studies of patients with anti-epiligrin cicatricial pemphigoid. J Dermatol 22: 829-835.
271. Yancey KB, Egan CA (2000). Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 284: 350-356.
272. Yeh SW, Ahmed B, Sami N, Razzaque Ahmed A (2003). Blistering disorders: diagnosis and treatment. Dermatol Ther 16: 214-223.
273. Yunis JJ, Mobini N, Yunis EJ et al (1994). Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci USA 91: 7747-7751.
274. Zillikens D, Kawahara Y, Ishiko A et al (1996). A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 106: 1333-1338.
275. Zillikens D (1999). Acquired skin disease of hemidesmosomes. J Dermatol Sci 20: 134-154.
276. Zillikens D, Ishiko A, Jonkman MF et al (2000). Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol 143: 1043-1049.